Developer docs
API playgroundTry for free, no card

Search company profiles

E25Bio

Full company profile

uuid00021tq

Namestring
E25Bio
Legal namestring
SUMO777
Websiteurl
e25bio.com
Company typeenum
Private
Founded yearint
2026
Descriptiontext

E25Bio is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that specializes in the development of rapid diagnostic tests for epidemic fever viruses, such as dengue, Zika, and related pathogens. The company operates with a small team (1-10 employees) and is privately held. Its core offering centers on rapid, point-of-care diagnostic assays designed to enable faster detection of epidemic-prone febrile illnesses, addressing an unmet need in outbreak response and clinical triage in both developed and resource-limited settings.

The company has secured approximately $10.1M across three funding rounds between 2019 and 2020. Its seed round in August 2019 was led by The Engine (MIT's tough-tech venture fund), with participation from Alumni Ventures and Castor Ventures, anchoring E25Bio within MIT's diagnostics and bioengineering ecosystem. A March 2020 round of $2M was led by Khosla Ventures with Blue Ivy Ventures, followed by a $5.82M round in August 2020 from the Bill & Melinda Gates Foundation and SBIR, signaling strategic alignment with global health and pandemic preparedness priorities.

The business model is structured around grant-funded and venture-backed R&D, with the long-term monetization pathway implicitly tied to commercialization of diagnostic test products through clinical, government, and global health channels. The company is led by co-founder and CEO Bobby Brooke Herrera alongside co-founder Lee Gehrke, combining operational and scientific leadership. Pricing, customer segments, and go-to-market details are not disclosed in the available data, consistent with a pre-commercial stage diagnostics developer.

Short descriptiontext

E25Bio is a Cambridge, MA-based biotechnology company founded in 2018 that develops rapid diagnostic tests for epidemic fever viruses, serving global health, clinical, and pandemic preparedness markets from a small (1-10 employee) R&D operation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rapid diagnostic tests, infectious disease diagnostics, epidemic fever viruses, point-of-care testing, outbreak diagnostics
Industry2 codes
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Rapid Infectious Disease Diagnostics
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

E25Bio develops rapid diagnostic tests for epidemic fever viruses, focused on point-of-care detection of infectious disease pathogens. The company's core work is in assay and kit development intended for outbreak and frontline clinical use. Diagnostic products are sold to institutional customers such as public health agencies, hospitals, and research organizations.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Rapid diagnostic tests for epidemic fever viruses
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

A leading molecular diagnostics company (owned by Danaher) whose GeneXpert system is widely deployed for infectious disease testing including outbreak pathogens — the dominant incumbent in rapid molecular diagnostics that E25Bio competes against.

TypeBroad incumbent
Description

bioMérieux subsidiary operating the FilmArray syndromic panel platform for infectious disease diagnostics, including panels covering fever-causing pathogens — directly comparable in target market (rapid syndromic infectious disease testing).

TypeEmerging player
Description

CRISPR-based diagnostics company developing rapid molecular tests for infectious diseases, including fever viruses. Comparable as a venture-backed emerging player in decentralized nucleic-acid-based rapid diagnostics.

TypeEmerging player
Description

CRISPR- and synthetic biology-driven diagnostics company building rapid, field-deployable tests for infectious diseases — closely aligned with E25Bio's mission of decentralized rapid testing for outbreak pathogens.

TypeEmerging player
Description

Developer of rapid molecular diagnostic systems for infectious diseases including respiratory and fever pathogens, focused on low-cost, portable platforms for global health — comparable in product profile and target LMIC markets.

TypeEmerging player
Description

Host-response diagnostics company developing rapid tests to distinguish bacterial vs viral infections — comparable as a venture-backed diagnostics startup targeting rapid infectious disease decision-making.

TypeEmerging player
Description

Diagnostics company developing rapid, near-patient testing platforms for newborn screening and infectious diseases — comparable in focus on rapid, decentralized diagnostic platforms and global health applications.

TypeBroad incumbent
Description

Global molecular diagnostics and sample-preparation leader with significant infectious disease test portfolio including outbreak pathogen assays — a broad incumbent competing for the same customer channels as E25Bio.

9Abbott (Diagnostics)
TypeBroad incumbent
Description

Diversified diagnostics giant whose ID NOW platform provides rapid molecular testing for influenza, RSV, and other infectious agents — a broad incumbent shaping rapid-test procurement standards in the same market segment.

10Corgenix / EKF Diagnostics
TypeRegional player
Description

EKF Diagnostics' Corgenix unit develops rapid immunodiagnostic tests targeting epidemic and neglected infectious diseases (e.g., Ebola, dengue) — closely comparable in niche focus on outbreak-related rapid diagnostics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

E25Bio

Rapid Infectious Disease Diagnosticse25bio.com

E25Bio is a Cambridge, MA-based biotechnology company founded in 2018 that develops rapid diagnostic tests for epidemic fever viruses, serving global health, clinical, and pandemic preparedness markets from a small (1-10 employee) R&D operation.

What E25Bio does

E25Bio is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that specializes in the development of rapid diagnostic tests for epidemic fever viruses, such as dengue, Zika, and related pathogens. The company operates with a small team (1-10 employees) and is privately held. Its core offering centers on rapid, point-of-care diagnostic assays designed to enable faster detection of epidemic-prone febrile illnesses, addressing an unmet need in outbreak response and clinical triage in both developed and resource-limited settings.

The company has secured approximately $10.1M across three funding rounds between 2019 and 2020. Its seed round in August 2019 was led by The Engine (MIT's tough-tech venture fund), with participation from Alumni Ventures and Castor Ventures, anchoring E25Bio within MIT's diagnostics and bioengineering ecosystem. A March 2020 round of $2M was led by Khosla Ventures with Blue Ivy Ventures, followed by a $5.82M round in August 2020 from the Bill & Melinda Gates Foundation and SBIR, signaling strategic alignment with global health and pandemic preparedness priorities.

The business model is structured around grant-funded and venture-backed R&D, with the long-term monetization pathway implicitly tied to commercialization of diagnostic test products through clinical, government, and global health channels. The company is led by co-founder and CEO Bobby Brooke Herrera alongside co-founder Lee Gehrke, combining operational and scientific leadership. Pricing, customer segments, and go-to-market details are not disclosed in the available data, consistent with a pre-commercial stage diagnostics developer.

E25Bio firmographics

Firmographics
Name
E25Bio
Legal name
SUMO777
Website
https://e25bio.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
E25Bio is a Cambridge, MA-based biotechnology company founded in 2018 that develops rapid diagnostic tests for epidemic fever viruses, serving global health, clinical, and pandemic preparedness markets from a small (1-10 employee) R&D operation.
Ownership category
akta.pro rank

E25Bio industry classification

Industry
Product category
Rapid Infectious Disease Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • Rapid diagnostic tests
  • Infectious disease diagnostics
  • Epidemic fever viruses
  • Point-of-care testing
  • Outbreak diagnostics

Where E25Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

E25Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

E25Bio product offering

Product offering

Core offering

E25Bio develops rapid diagnostic tests for epidemic fever viruses, focused on point-of-care detection of infectious disease pathogens. The company's core work is in assay and kit development intended for outbreak and frontline clinical use. Diagnostic products are sold to institutional customers such as public health agencies, hospitals, and research organizations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rapid diagnostic tests for epidemic fever viruses

Companies that use E25Bio

Customer profile

Ideal customer profiles1 record

E25Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

E25Bio partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights4 records

E25Bio competitors and assessment

Company assessment

Broad incumbents

  • Cepheid (Danaher): A leading molecular diagnostics company (owned by Danaher) whose GeneXpert system is widely deployed for infectious disease testing including outbreak pathogens — the dominant incumbent in rapid molecular diagnostics that E25Bio competes against.
  • BioFire Diagnostics (bioMérieux): bioMérieux subsidiary operating the FilmArray syndromic panel platform for infectious disease diagnostics, including panels covering fever-causing pathogens — directly comparable in target market (rapid syndromic infectious disease testing).
  • QIAGEN: Global molecular diagnostics and sample-preparation leader with significant infectious disease test portfolio including outbreak pathogen assays — a broad incumbent competing for the same customer channels as E25Bio.
  • Abbott (Diagnostics): Diversified diagnostics giant whose ID NOW platform provides rapid molecular testing for influenza, RSV, and other infectious agents — a broad incumbent shaping rapid-test procurement standards in the same market segment.

Emerging players

  • Mammoth Biosciences: CRISPR-based diagnostics company developing rapid molecular tests for infectious diseases, including fever viruses. Comparable as a venture-backed emerging player in decentralized nucleic-acid-based rapid diagnostics.
  • Sherlock Biosciences: CRISPR- and synthetic biology-driven diagnostics company building rapid, field-deployable tests for infectious diseases — closely aligned with E25Bio's mission of decentralized rapid testing for outbreak pathogens.
  • Akonni Biosystems: Developer of rapid molecular diagnostic systems for infectious diseases including respiratory and fever pathogens, focused on low-cost, portable platforms for global health — comparable in product profile and target LMIC markets.
  • Inflammatix: Host-response diagnostics company developing rapid tests to distinguish bacterial vs viral infections — comparable as a venture-backed diagnostics startup targeting rapid infectious disease decision-making.
  • Baebies: Diagnostics company developing rapid, near-patient testing platforms for newborn screening and infectious diseases — comparable in focus on rapid, decentralized diagnostic platforms and global health applications.

Regional players

  • Corgenix / EKF Diagnostics: EKF Diagnostics' Corgenix unit develops rapid immunodiagnostic tests targeting epidemic and neglected infectious diseases (e.g., Ebola, dengue) — closely comparable in niche focus on outbreak-related rapid diagnostics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

E25Bio social profiles

Digital presence

E25Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

E25Bio leadership team

Management profile

Number of profiles

Profiles2 records

E25Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

E25Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about E25Bio

What does E25Bio do?

E25Bio develops rapid diagnostic tests for epidemic fever viruses, focused on point-of-care detection of infectious disease pathogens. The company's core work is in assay and kit development intended for outbreak and frontline clinical use. Diagnostic products are sold to institutional customers such as public health agencies, hospitals, and research organizations.

Is E25Bio a public or private company?

E25Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was E25Bio founded?

E25Bio was founded in 2026. It employs 1 to 10 people.

Where is E25Bio based?

E25Bio is headquartered in Cambridge, United States, in the North America region.

Who are E25Bio's main competitors?

Broad incumbents on record are Cepheid (Danaher), BioFire Diagnostics (bioMérieux), QIAGEN and Abbott (Diagnostics). Emerging players are Mammoth Biosciences, Sherlock Biosciences, Akonni Biosystems, Inflammatix and Baebies. Corgenix / EKF Diagnostics is listed as a regional player.

Does E25Bio have an API?

No public API is recorded for E25Bio.

What industry is E25Bio in?

E25Bio's product category is Rapid Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Global BiodefenseWhy You Can’t Find Cheap At-Home Covid Tests in the U.S.The U.S. lacks cheap at-home Covid tests because the FDA has over 3,000 emergency use authorization applications and faces manufacturing bottlenecks. Prices range from $14 to over $50 per test, and startups like Blink Science and E25Bio face regulatory delays. The Biden administration recently allocated $3 billion to boost supply, but scaling up takes time.PR NewswireLabCentral Launches COVID-19 Rapid Testing Consortium in Partnership with BioLabs and E25BioLabCentral has partnered with BioLabs and E25Bio to launch the Cambridge Consortium for Rapid COVID-19 Tests (CCRCT), aimed at validating E25Bio's novel DART rapid antigen test that can produce results within 15 minutes compared to the days-long turnaround of standard PCR tests. The three-month clinical trial, which began in early September 2020 with over 300 volunteer scientists from LabCentral and BioLabs, is evaluating whether the self-administered at-home test can serve as an affordable screening tool for asymptomatic populations to enable a safer return to work and school. The consortium is working toward obtaining CLIA certification, which would allow it to accept human samples for diagnostic testing and serve as a resource for other companies developing rapid tests.Boston HeraldMassachusetts biotech startups making progress on coronavirus tests, vaccinesE25Bio, a Cambridge biotech startup, pivoted in February to develop a rapid coronavirus antigen test, now in clinical trials awaiting FDA approval. Other startups in the same coworking space are also shifting to tests, vaccines, and therapeutics. Fruehauf urged continued effort and warned that a broadly useful vaccine may take nine to 12 months.FinSMEsE25Bio Closes $2M in Financing to Diagnose Coronavirus - FinSMEsE25Bio, a Cambridge-based rapid diagnostic test developer, raised $2M in financing from Khosla Ventures. The funds will support research, clinical studies, and scaling its coronavirus test after EUA approval. The company, founded in 2018, uses nanoparticle technology for infectious disease detection.VC News DailyE25Bio Lands $2M Seed FundingE25Bio, a Cambridge, Massachusetts-based developer of rapid nanoparticle diagnostic tests for infectious diseases, has raised $2 million in seed funding from Khosla Ventures. The company, founded in 2018 and based at MIT's The Engine incubator, will use the funding to support R&D, clinical studies, and scaling its diagnostic tests for diseases including dengue, zika, and the novel coronavirus upon receiving FDA Emergency Use Authorization approval. The company's tests can deliver results in 15 minutes or less using technology developed by MIT researchers.Pulse 2.0Diagnostic Technology Company E25Bio Raises $2.3 MillionE25Bio raised $2.3 million in a seed round led by The Engine, with participation from Alumni Ventures Group and Alejandro Chavez. The company's rapid diagnostic test screens for active viruses in minutes, targeting mosquito-borne diseases like dengue, chikungunya, and Zika. It has completed clinical studies and initiated regulatory submissions.PR NewswireDCN Diagnostics and E25Bio Partner for the Development of a Product for Early Detection of Infectious DiseasesDCN Dx and E25Bio have announced a partnership to design, develop, and manufacture a rapid diagnostic test for the early detection of dengue, Chikungunya, and Zika viruses. The collaboration leverages E25Bio's technology and DCN Dx's manufacturing capabilities to create a low-cost, point-of-care device aimed at global epidemiological analysis. This initiative seeks to improve access to swift diagnostics in endemic regions to help manage disease outbreaks.